DEVELOPMENT OF DISCRIMINATING AND IN VIVO CORRELATING DISSOLUTION METHOD FOR BCS CLASS II CILOSTAZOL IMMEDIATE RELEASE TABLET FORMULATION
DOI:
https://doi.org/10.5614/api.v51i1.27371Keywords:
Cilostazol, Biopharmaceutics Classification System, Biorelevant medium, discriminating dissolution method, BioavailabilityAbstract
Cilostazol is used to treat symptoms of intermittent claudication in peripheral vascular disease. It is classified as a Class II drug in the Biopharmaceutics Classification System, exhibiting low solubility and poor bioavailability, which makes pharmacokinetic evaluation essential during product development. This study aimed to develop a discriminative dissolution medium and method reliable for predicting the in vivo results of Cilostazol tablets. In this study, dissolution methods were developed according to regulatory guidelines using water (per USP monograph) and buffer solutions (pH 1.2, 4.5, and 6.8) supplemented with 0.05?0.30% sodium lauryl sulfate (SLS). Testing was performed on a formulated sample and a comparator product (n=12 each) at 37 0.5 C, with varying paddle speeds (50?75 rpm) and volumes (500?900 mL). The most biorelevant and discriminating condition?a pH 1.2 buffer with 0.05% SLS, 50 rpm paddle speed, and 500 mL volume?was identified as the most suitable in vitro profile for distinguishing the test formulation from the comparator and for predicting in vivo results.
References
Bibi M, Din F ud, Anwar Y, Alkenani NA, Zari AT, Mukhtiar M, Abu Zeid IM, Althubaiti EH, Nazish H, Zeb A, Ullah I, Khan GM, Choi HG, 2022, Cilostazol-loaded solid lipid nanoparticles: Bioavailability and safety evaluation in an animal model, J Drug Deliv Sci Technol 74, doi: 10.1016/j.jddst.2022.103581.
Bredael GM, Liang S, Hahn D, 2015, A strategy for quality control dissolution method development for immediate-release solid oral dosage forms, Dissolution Technol 22(3):10?16, doi: 10.14227/DT220315P10.
Jangla P, Raut R, 2024, Selection and Parameters Affecting Dissolution Media, Dissolution Technol 31(2):78?84, doi: 10.14227/DT310224P78.
Jinno JI, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T, 2008, In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol, J Control Release 130(1):29?37, doi: 10.1016/j.jconrel.2008.05.013.
Kamada N, Yamada K, Mukai T, Odomi M, Ogawara K, Kimura T, Higaki K. 2009. IVIVC for oral absorption of cilostazol, a BCS class II drug, based on GITA (GI-transit-absorption) model, Paper Presented at: 24th JSSX Annual Meeting in Kyoto, Kyoto, Japan.
Kherallah RY, Khawaja M, Olson M, Angiolillo D, Birnbaum Y, 2022, Cilostazol: a Review of Basic Mechanisms and Clinical Uses, Cardiovasc Drugs Ther 36(4):777?792, doi: 10.1007/s10557-021-07187-x.
Lagace M, Gravelle L, di Maso M, McClintock S, 2004, Developing a discriminating dissolution procedure for a dual active pharmaceutical product with unique solubility characteristics, Dissolution Technol 11(1):13?17, doi: 10.14227/DT110104P13.
Min KA, Kim NY, Jin MJ, Kim D, Ma Y, Karna S, Park YJ, 2024, In Vitro/In Vivo Correlation of Two Extended-Release Cilostazol Formulations, Pharmaceuticals 17(6):1?16, doi: 10.3390/ph17060787.
Schr K, 2002, The pharmacology of cilostazol, Diabetes Obes Metab 4(SUPPL. 2):14?19, doi: 10.1046/j.1463-1326.2002.0040s2s14.x.
Shah VP, Lesko LJ, Fan J, Fleischer N, Handerson J, Malinowski H, Makary M, Ouderkirk L, Bay S, Sathe P, Singh GJP, Tillman L, Tsong Y, Williams RL, 1997, FDA guidance for industry 1 dissolution testing of immediate release solid oral dosage forms. Dissolution Technol, 4(4):15?22, doi: 10.14227/DT040497P15.
Toyobuku H, Tamai I, Ueno K, Tsuji A, 2003, Limited influence of P?glycoprotein on small?intestinal absorption of cilostazol a high absorptive permeability drug, J Pharm Sci 92(11):2249-2259, doi: 10.1002/jps.10490.
United States Pharmacopeia. 2025a. Cilostazol Tablets.
United States Pharmacopeia. 2025b. Buffer Solutions.
